<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364813">
  <stage>Registered</stage>
  <submitdate>1/10/2013</submitdate>
  <approvaldate>3/10/2013</approvaldate>
  <actrnumber>ACTRN12613001106729</actrnumber>
  <trial_identification>
    <studytitle>The effects of zopiclone on obstructive sleep apnoea</studytitle>
    <scientifictitle>The effects of zopiclone on obstructive sleep apnoea severity and symptoms of daytime sleepiness and measures of alertness</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>ZOPOSA</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive sleep apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zopiclone (7.5mg) once a day immediately before going to bed, for 30 days. Taken orally. 
Adherence will be monitored via drug tablet return</interventions>
    <comparator>Placebo, once a day immediately before going to bed, for 30 days. Taken orally.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if zopiclone reduces the apnoea/hypopnoea index (AHI) via overnight polysomnographyin in sleep apnoea patients with low to moderate arousal thresholds</outcome>
      <timepoint>1 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptoms of sleepiness as measured by standardized questionnaires (KSS, ESS, Leeds and FOSQ) </outcome>
      <timepoint>In the morning after Night 1 of the study intervention (KSS and Leeds) 
In the evening before the study intervention  at 1 month (KSS, ESS and FOSQ) and 
The following morning after the study intervention at 1 month (KSS and Leeds)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AusEd driving simulator performance</outcome>
      <timepoint>Night 1 in the morning after the study intervention and 1 month in the morning after the study intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Other standard measures of sleep apnoea severity as determined during the polysomnogram (e.g. sleep efficiency, arousal index, event duration, nadir SaO2 and AHI on night 1)</outcome>
      <timepoint>Night 1 and 1 month, both after the study intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men and women with obstructive sleep apnoea (OSA)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-People without OSA or who are currently on continuous positive airway pressure therapy for OSA
-People with high arousal thresholds (average nadir epiglottic pressure just prior to arousal &lt;-25cmH2O)  as determined by overnight polysomnogram (sleep study) during a screening visit.
-Known allergy or previous adverse reaction zopiclone 
-Pregnant or nursing mothers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>8/10/2013</anticipatedstartdate>
    <actualstartdate>9/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>2/02/2016</actualenddate>
    <samplesize>30</samplesize>
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <postcode>2031 - Randwick</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>Woolcock Institute of Medical Research
University of Sydney
431 Glebe point road
Glebe, NSW 2037</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>National Health and Medical Research Council GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Neuroscience Research Australia</sponsorname>
      <sponsoraddress>Barker Street
Randwick
NSW 2031</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Prince of Wales Hospital</sponsorname>
      <sponsoraddress>High Street
Randwick, NSW, 2031</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to examine the effects of nightly administration of a standard dose of a common sleeping pill (sedative) zopiclone, over one month, on sleep apnoea severity, symptoms of daytime sleepiness, and measures of alertness in sleep apnoea patients</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Sydney Local Health District Human Research Ethics Committee</ethicname>
      <ethicaddress>Room G71 East Wing
Edmund Blacket Building
Prince of Wales Hospital
Cnr High and Avoca Streets 
RANDWICK, NSW 2031
</ethicaddress>
      <ethicapprovaldate>29/01/2013</ethicapprovaldate>
      <hrec>12/183 (HREC/12/POWH/394)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia Barker Street Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia Barker Street Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia Barker Street Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia Barker Street Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>